Yinghe Technology Received Buy Rating: Vape Business Achieved Revenue of 470 Million USD in 2023

Business by 2FIRSTS, edited by Sophia
May.06.2024
Yinghe Technology Received Buy Rating: Vape Business Achieved Revenue of 470 Million USD in 2023
Yinghe Technology's e-cigarette business shows rapid growth, gaining market share in the UK and Europe, attracting investor interest.

On May 4th, Zhongtai Securities conducted research on Yinghe Technology (300457) and released a research report titled "Leading in Lithium Battery Equipment, Solid State Battery Equipment, and Continued Benefits in the e-cigarette Business." The report recommended a buy rating for Yinghe Technology (300457).

 

Yinghe Technology Received Buy Rating: Vape Business Achieved Revenue of 470 Million USD in 2023
Research report original text | Image source: Yinghe Technology

 

2FIRSTS compiled the following information based on the original article.

 

Yinghe Technology's ODM business for e-cigarettes is expected to become the company's second growth trend. The e-cigarette business primarily focuses on brand services, providing customers with e-cigarettes, pods, vaporizers, and other e-cigarette accessories. In 2023, Yinghe Technology's e-cigarette business achieved rapid growth, with operating income reaching 3.341 billion yuan (470 Million USD), accounting for 34% of the company's total operating income.

 

The e-cigarette products offered by Sikary's subsidiary have gained wide popularity among European users due to their rich flavors and high quality. Particularly, the SKE brand has shown outstanding performance in the UK market, with its market share continuously soaring. Sikary has achieved groundbreaking developments in its brand operations in the UK and other European countries. By August 2023, SKE's market share in the UK had risen to third place.

 

Yinghe Technology has over 5000 employees and has established a branch factory in Shajing, with a manufacturing base of over 20,000 square meters, ensuring high-quality product output with a monthly shipment volume of over 20 million units. On September 21, 2022, the company's subsidiary e-cigarette company, Sikary, obtained a tobacco monopoly production enterprise license, which will help seize industrial development opportunities and further expand and layout the new tobacco market both domestically and overseas.

 

The company is actively expanding into overseas markets, especially in the UK where it has established a wholly-owned subsidiary to expedite the TPD certification of new products and increase market share.

 

Although the e-cigarette industry is rapidly growing, the company has also highlighted potential policy risks, as the new tobacco industry is still in its early stages of development and policy changes domestically and internationally may impact business growth.

 

Yinghe Technology receives its first "buy" rating, with expectations of continued growth in net profits in the coming years, benefiting from developments in new technologies and expansion into overseas markets.

 

In summary, Zhongtai Securities stated that Yinghe Technology's e-cigarette business has gained a foothold in the global market through continuous product innovation and market expansion, demonstrating good market competitiveness and growth potential. At the same time, the company is actively addressing potential policy and market risks to maintain the sustainable and healthy development of its business.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Los Angeles Cracks Down on Illicit Flavored Vapes and Counterfeit Goods: 12 Businesses Searched, 24 Arrested, Eight Truckloads Seized
Los Angeles Cracks Down on Illicit Flavored Vapes and Counterfeit Goods: 12 Businesses Searched, 24 Arrested, Eight Truckloads Seized
Los Angeles authorities searched 12 businesses and arrested 24 people during a multi-agency operation targeting illicit flavored vaping products, flavored cigarettes and counterfeit merchandise on October 22, 2026. The Los Angeles County Sheriff's Department said approximately eight tractor-trailer loads of merchandise were seized. Alleged violations involved flavored tobacco sales restrictions, tobacco licensing requirements and counterfeit trademark laws. Local, state and federal agencies participated. Authorities have not disclosed the number, brands or value of vaping products seized. Investigations remain ongoing.
Enforcement
Oct.28
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Juul Labs UK has introduced an upgraded JUUL2 Starter Kit for the UK market in October 2026, retaining a recommended retail price of £9.99 while doubling the number of included pods from two to four. The kit contains Crisp Menthol, Virginia Tobacco, Mango and Watermelon pods. The updated device replaces the previous proprietary charging dock with a USB-C port and offers longer battery life. The kit also features reduced packaging and retains a two-year limited warranty. Distribution is scheduled through major UK retailers, wholesalers, convenience stores and the JUUL UK website.
product
Oct.15
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13